Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
5(100.0%)
5Total
Phase 1(5)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT03914443Phase 1Completed

A Feasibility Trial of Nivolumab With Neoadjuvant CF or DCF Therapy for Locally Advanced Esophageal Carcinoma

Role: collaborator

NCT02096614Phase 1Completed

Investigator Initiated Phase 1 Study of TBI-1201

Role: collaborator

NCT02946671Phase 1Completed

Study of Pre-operative Combination Therapy With Mogamulizumab and Nivolumab Against Solid Cancer Patients

Role: collaborator

NCT02999295Phase 1Completed

A Phase 1/2 Study of Ramucirumab Plus Nivolumab in Participants With Gastric or GEJ Cancer

Role: collaborator

NCT02366546Phase 1Unknown

Investigator Initiated Phase 1 Study of TBI-1301

Role: collaborator

All 5 trials loaded